系统性硬化症相关间质性肺病的抗酸治疗:德国系统性硬化症网络的长期结局
该研究回顾性分析德国系统性硬化症网络(DNSS)2003年起登记的系统性硬化症(SSc)及SSc相关间质性肺病(SSc-ILD)患者,比较有或无胃食管反流病(GERD)及用或不用质子泵抑制剂(PPI)的生存结局。结果显示GERD与总生存(OS)和无进展生存(PFS)下降无关,而SSc-ILD患者使用PPI与OS和PFS改善相关。
要点
- SSc患者中GERD患病率为63%(2693/4306),SSc-ILD患者中为62%(1204/1931)。
- GERD与SSc或SSc-ILD患者OS或PFS下降均无关。
- SSc-ILD患者使用PPI与1年和5年OS及PFS改善相关(P<0.0001)。
核心结论
- GERD对SSc或SSc-ILD患者的生存无影响。
- PPI改善SSc-ILD患者的生存。
- 需要对照的前瞻性试验来证实此发现。
研究设计与样本
- 回顾性分析德国系统性硬化症网络(DNSS)数据库(2003年起)中SSc和SSc-ILD患者。
- 采用Kaplan-Meier分析比较有GERD vs 无GERD(SSc和SSc-ILD)以及用PPI vs 不用PPI(仅SSc-ILD)的OS和PFS。
- 进展定义为预测用力肺活量百分比下降≥10%或单次呼吸一氧化碳弥散量下降≥15%,或死亡。
主要发现
- 2693/4306(63%)登记SSc患者和1204/1931(62%)SSc-ILD患者有GERD。
- GERD与两个队列中OS下降或PFS下降均无关。
- SSc-ILD中,PPI使用 vs 不用PPI:1年OS为98.4%(95%CI:97.6, 99.3;n=760) vs 90.8%(87.9-93.8;n=290),5年OS为91.4%(89.2-93.8;n=357) vs 70.9%(65.2-77.1;n=106),P<0.0001。
- SSc-ILD中,PPI使用 vs 不用PPI:1年PFS为95.9%(94.6-97.3;n=745) vs 86.4%(82.9-90.1;n=278),5年PFS为66.8%(63.0-70.8;n=286) vs 45.9%(39.6-53.2;n=69),P<0.0001。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需要对照的前瞻性试验来证实此发现。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Gastroesophageal reflux disease (GERD) occurs frequently in patients with SSc. We investigated whether the presence of GERD and/or the use of anti-acid therapy, specifically proton-pump inhibitors (PPIs), are associated with long-term outcomes, especially in SSc-associated interstitial lung disease (SSc-ILD). METHODS: We retrospectively analysed patients with SSc and SSc-ILD from the German Network for Systemic Sclerosis (DNSS) database (2003 onwards). Kaplan-Meier analysis compared overall survival (OS) and progression-free survival (PFS) in patients with GERD vs without GERD (SSc and SSc-ILD), and PPI vs no PPI use (SSc-ILD only). Progression was defined as a decrease in either percentage predicted forced vital capacity of ≥10% or single-breath diffusing capacity for carbon monoxide of ≥15%, or death. RESULTS: It was found that 2693/4306 (63%) registered patients with SSc and 1204/1931 (62%) with SSc-ILD had GERD. GERD was not associated with decreased OS or decreased PFS in patients in either cohort. In SSc-ILD, PPI use was associated with improved OS vs no PPI use after 1 year [98.4% (95% CI: 97.6, 99.3); n = 760 vs 90.8% (87.9-93.8); n = 290] and after 5 years [91.4% (89.2-93.8); n = 357 vs 70.9% (65.2-77.1); n = 106; P < 0.0001]. PPI use was also associated with improved PFS vs no PPI use after 1 year [95.9% (94.6-97.3); n = 745 vs 86.4% (82.9-90.1); n = 278] and after 5 years [66.8% (63.0-70.8); n = 286 vs 45.9% (39.6-53.2); n = 69; P < 0.0001]. CONCLUSION: GERD had no effect on survival in SSc or SSc-ILD. PPIs improved survival in patients with SSc-ILD. Controlled, prospective trials are needed to confirm this finding.
引用
- Kreuter M, Bonella F, Blank N, et al. Anti-acid therapy in SSc-associated interstitial lung disease: long-term outcomes from the German Network for Systemic Sclerosis. Rheumatology (Oxford). 2023. PMID: 36708008. doi:10.1093/rheumatology/kead023
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。